What Has Been the Growth Trajectory for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market in Recent Years?
The chronic obstructive pulmonary disease (copd) treatment market has seen considerable growth due to a variety of factors.
•The market size for the treatment of chronic obstructive pulmonary disease (COPD) has noted impressive expansion in the past few years. The value of the market is expected to surge from $20.84 billion in 2024 to $21.94 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.3%.
The historical growth of this sector is owing to factors such as the prevalence of smoking and tobacco consumption, progress in inhalation treatments, educational programs prompting early detection, governmental actions promoting respiratory health, and research and innovation in the field of pulmonology.
How Does the Forecast Look for the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The chronic obstructive pulmonary disease (copd) treatment market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for treating chronic obstructive pulmonary disease (COPD) is predicted to undergo sizable growth in the upcoming years, expanding to $27.74 billion in 2029 with a compound annual growth rate (CAGR) of 6.0%.
This anticipated growth throughout the forecast period is a result of factors such as advancements in personalized medicine and biomarker research, the development of biologic therapies and targeted interventions, concerns related to air quality and environmental factors, global initiatives aiming to curtail smoking, and partnerships formed for drug development. Some noteworthy trends projected for the forecast period encompass the application of digital health solutions for managing COPD, the advent of biologic therapies specifically for COPD, the rise of personalized medicine, the use of combined therapies and inhalers, efforts to diagnose and intervene early, and programs intended for pulmonary rehabilitation.
What Are the Critical Driver Fuelling the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market's Growth?
The growing prevalence of lung disorders is likely to fuel the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. These diseases impair the proper functioning of the lungs, with the most common types including asthma, COPD, and lung cancer. Primarily, COPD treatment serves to manage lung disease, slow its progression, control symptoms, and prevent further damage to the lungs through the use of inhalers and medication. For example, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a US-based non-profit entity, reported in September 2022 that 3.2 million individuals die yearly from COPD, affecting an approximate 200 million people worldwide. It also highlighted how 262 million people globally were impacted by asthma in 2022, forecasting an increase in such figures over time. Furthermore, in 2023, the US-based LUNGevity Foundation estimated that 127,000 Americans would succumb to lung cancer annually. As such, the rising occurrence of lung disease underpins the growing demand in the COPD treatment market.
How Is the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market segmented?
The chronic obstructive pulmonary disease (COPD) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Pre-Book The Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Product innovation is becoming a notable trend within the COPD treatment market, as major corporations strive to build and maintain their market presence through the creation of new and innovative products. A prime example of this occurred in April 2022 when UK-based pharmaceutical and biotechnology company, GlaxoSmithKline plc (GSK), introduced Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) in India. This product, a first-of-its-kind single-inhaler triple therapy (SITT), is formulated to manage and alleviate symptoms of COPD in individuals who are 18 years of age or older. It operates in a manner akin to natural corticosteroid hormones, impacting immune system activity by binding to specific immune cell receptors. Furthermore, it assists in reducing lung airway inflammation, thereby easing breathing difficulties.
Who Are the Key Players in the Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include:
• Almirall S.A.
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Abbott Laboratories
• Chiesi Farmaceutici S.p.A
• Mylan N.V.
• Orion Corporation
• Sunovion Pharmaceuticals Inc.
• Dr. Reddy’s Laboratories Ltd.
• Circassia Group PLC
• Kyowa Kirin Co. Ltd.
• Sanofi S.A
• Theravance Biopharma Inc.
• Verona Pharmaceuticals plc
• Alcon Laboratories Inc.
• Amgen Inc.
• Apotex Inc.
• Aurobindo Pharma Limited
• Biocon Limited
• Biogen Inc.
• Bristol-Myers Squibb Company
• Cipla Limited
• Eli Lilly and Company
• Glenmark Pharmaceuticals Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Meda AB
• Mundipharma International Limited
• Pfizer Inc.
What Is The Most Dominant Region In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
